Skip to Main Content

Paper Details

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Sci Transl Med
104
2019
CRPC, CRPC-NE, DLL3, DLL3-expressing prostate cancer xenografts, DLL3-negative models, Delta-like protein 3, NE, RB1, Rovalpituzumab, Rovalpituzumab tesirine, SC16LD6, advanced prostate cancer, benign prostate, castration-resistant neuroendocrine prostate cancer, castration-resistant prostate adenocarcinomas, circulating tumor cells, delta-like protein 3, localized prostate cancer, lung cancer, metastatic prostate cancer, neuroendocrine, neuroendocrine prostate cancer, patient, patients, small, small cell, small cell neuroendocrine prostate cancer
Author NameAffiliation
Loredana Puca
Loredana PucaCaryl and Israel Englander Institute for Precision Medicine
Verena SailerCaryl and Israel Englander Institute for Precision Medicine
Verena Sailer
Michael Sigouros
Aram VosoughiCaryl and Israel Englander Institute for Precision Medicine
Aram Vosoughi
Samaneh MotanaghCaryl and Israel Englander Institute for Precision Medicine
Samaneh Motanagh
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine
Andrea SbonerInstitute for Computational Biomedicine
Andrea Sboner
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine
Andrea Sboner
Andrea SbonerInstitute for Computational Biomedicine
Yuzhuo WangUniversity of British Columbia
Ryan Dittamore
David S Rickman
David M Nanus
David M NanusCaryl and Israel Englander Institute for Precision Medicine
Scott T Tagawa
Scott T TagawaCaryl and Israel Englander Institute for Precision Medicine
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine
Olivier ElementoInstitute for Computational Biomedicine
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine
Olivier ElementoInstitute for Computational Biomedicine
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine
Mark A Rubin
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine
Mark A Rubin
Himisha Beltran
Himisha BeltranCaryl and Israel Englander Institute for Precision Medicine
Himisha BeltranDana Farber Cancer Institute, Harvard Medical School
Himisha Beltran
Himisha BeltranCaryl and Israel Englander Institute for Precision Medicine
Himisha BeltranDana Farber Cancer Institute, Harvard Medical School
  • 1 - 36

Datasets

Release 1.2